和黄医药(00013)金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业及上海金浦志佰合企业管理合伙企业作为买方

智通财经2025-03-02

智通财经APP讯，和黄医药(00013)发布公告，于2025年2月28日，根据金浦健服购股协议，金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业(有限合伙)(作为金浦健服买方基金)及上海金浦志佰合企业管理合伙企业(有限合伙)(作为指定买方)，分别购买上海和黄药业25.1247%及9.8753%的股权，合共相当于所有金浦健服待售股份。鉴于公司于过去二十年已在中国建立起强大的业务基础，公司会将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2516351987?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-02 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516351987","market":"hk","top_or_hot":-1,"title":"和黄医药(00013)金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业及上海金浦志佰合企业管理合伙企业作为买方","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，于2025年2月28日，根据金浦健服购股协议，金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业(有限合伙)(作为金浦健服买方基金)及上海金浦志佰合企业管理合伙企业(有限合伙)(作为指定买方)，分别购买上海和黄药业25.1247%及9.8753%的股权，合共相当于所有金浦健服待售股份。鉴于公司于过去二十年已在中国建立起强大的业务基础，公司会将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256613.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013)金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业及上海金浦志佰合企业管理合伙企业作为买方</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013)金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业及上海金浦志佰合企业管理合伙企业作为买方\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-02 19:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1256613.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，于2025年2月28日，根据金浦健服购股协议，金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业(有限合伙)(作为金浦健服买方基金)及上海金浦志佰合企业管理合伙企业(有限合伙)(作为指定买方)，分别购买上海和黄药业25.1247%及9.8753%的股权，合共相当于所有金浦健服待售股份。鉴于公司于过去二十年已在中国建立起强大的业务基础，公司会将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256613.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1256613.html","article_id":"2516351987","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516351987","pubTimestamp":1740913649,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"鉴于公司于过去二十年已在中国建立起强大的业务基础，公司会将建议出售事项所得款项再次投资于其在中国经营的业务。是次出售将促进资源分配，使这些资源可以重新调配至公司在中国开展的创新性举措，特别是旨在强化其研发能力以及扩大其生产及商业化基础设施的举措。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159830":"上海金","BK1587":"次新股","BK1191":"制药","BK4585":"ETF&股票定投概念","HCM":"和黄医药","BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","00013":"和黄医药","BK1588":"回港中概股"},"translate_title":"Chi-Med (00013) Gimpo Health Services Equity Investment Management designated Shanghai Gimpo Zhicheng Private Equity Investment Fund Partnership and Shanghai Gimpo Zhibaihe Enterprise Management Partnership as buyers","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159830":1,"00013":1,"HCM":1},"content_text":"智通财经APP讯，和黄医药(00013)发布公告，于2025年2月28日，根据金浦健服购股协议，金浦健服股权投资管理指定上海金浦志诚私募投资基金合伙企业(有限合伙)(作为金浦健服买方基金)及上海金浦志佰合企业管理合伙企业(有限合伙)(作为指定买方)，分别购买上海和黄药业25.1247%及9.8753%的股权，合共相当于所有金浦健服待售股份。鉴于公司于过去二十年已在中国建立起强大的业务基础，公司会将建议出售事项所得款项再次投资于其在中国经营的业务。是次出售将促进资源分配，使这些资源可以重新调配至公司在中国开展的创新性举措，特别是旨在强化其研发能力以及扩大其生产及商业化基础设施的举措。此战略重点将使公司得以更好地把握其未来的发展机遇。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516351987","isCrawlerRequest":true}